Sculati Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Sculati Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.46M	Sell	3,280 -80	-2%	-$37.3K	0.54%	55
2025 Q4	$1.52M	Buy	3,360 +32	+1%	+$13.8K	0.54%	54
2025 Q3	$1.3M	Buy	3,328 +149	+5%	+$62.3K	0.46%	59
2025 Q2	$1.42M	Buy	3,179 +242	+8%	+$112K	0.53%	57
2025 Q1	$1.42M	Buy	2,937 +381	+15%	+$178K	0.58%	49
2024 Q4	$1.03M	Buy	2,556 +25	+1%	+$11.6K	0.41%	59
2024 Q3	$1.18M	Buy	2,531 +579	+30%	+$278K	0.47%	58
2024 Q2	$915K	Buy	1,952 +507	+35%	+$220K	0.39%	61
2024 Q1	$604K	Buy	+1,445	New	+$611K	0.26%	72

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sculati Wealth Management's VRTX Position: Q1 2026 in Review

Sculati Wealth Management reduced its Vertex Pharmaceuticals (VRTX) stake by 2.4% in Q1 2026, selling an estimated $37.3K and leaving 3,280 shares worth $1.46M. The position accounts for 0.54% of the portfolio, ranked #55.

Sculati Wealth Management first reported a position in VRTX in Q1 2024 and has held it in 9 quarters since. The position peaked at $1.52M in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Sculati Wealth Management held 3,280 shares of Vertex Pharmaceuticals worth $1.46M as of Q1 2026.
Sculati Wealth Management sold 80 Vertex Pharmaceuticals shares in Q1 2026, an estimated $37.3K.
Vertex Pharmaceuticals made up 0.54% of Sculati Wealth Management's portfolio in Q1 2026, its #55 holding.
Sculati Wealth Management first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
Sculati Wealth Management's Vertex Pharmaceuticals position peaked at $1.52M in Q4 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Sculati Wealth Management's 13F filing for Q1 2026, filed 9 Apr 2026.